PEDIATRICS Vol. 58 No. 3 September 1976, pp. 423-431
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gross, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, M. D.

Growth of Hyperkinetic Children Taking Methylphenidate, Dextroamphetamine, or Imipramine/Desipramine

Mortimer D. Gross M.D.1

1 Department of Psychiatry, University of Illinois Medical Center, Chicago

One hundred children with the hyperkinetic syndrome or minimal brain dysfunction syndrome were treated with medication: 60 with methylphenidate (Ritalin), 24 with dextroamphetamine (Dexedrine), and 16 with either imipramine or desipramine. The duration of treatment was for a minimum of two years, and averaged five years, with an average follow-up of six years from the onset of treatment. Their weight and height had been measured prior to treatment, and these and subsequent measurements were converted to percentiles, using the tables of norms of the Iowa City study. Initially there was a diminution in expected weight, but not height, but after a few years the growth in weight and height was found to be greater than predicted from the norms to a statistically significant degree. Gains in weight and height were greater for those whose medication had been stopped prior to the final measurements than for those still taking medication; but these differences did not reach statistical significance. No correlations were found between dosage level and changes in weight and height percentiles. It is concluded that there is no stunting of growth from the long-term use of methylphenidate, dextroamphetamine, or imipramine/desipramine in children. Any slowing of growth when treatment is first started is compensated for later on, both while the patient is still taking the medication, and after discontinuing it.

Submitted on August 22, 1975
Accepted on December 4, 1975




This article has been cited by other articles:


Home page
 Arch. Dis. Child.Home page
A Poulton
Growth on stimulant medication; clarifying the confusion: a review
Arch. Dis. Child., August 1, 2005; 90(8): 801 - 806.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
Subcommittee on Attention-Deficit/Hyperactivity Di and Committee on Quality Improvement
Clinical Practice Guideline: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity Disorder
Pediatrics, October 1, 2001; 108(4): 1033 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
K. K.S. Voeller
Clinical Management of Attention Deficit Hyperactivity Disorder
J Child Neurol, January 1, 1991; 6(1_suppl): S51 - S67.
[Abstract] [PDF]